MediLink Therapeutics announced interim analysis results from TAISHAN‑302, its phase III registrational clinical trial evaluating tambotatug pelitecan (Tam‑Peli, R&D code: YL201) versus topotecan in patients with relapsed small‑cell lung cancer (SCLC) who progressed after prior platinum‑based chemotherapy with or without a PD‑L1 inhibitor. The trial met its primary endpoint of overall survival (OS), with Tam‑Peli demonstrating a statistically significant and clinically meaningful OS benefit.
Trial Snapshot
| Item | Detail |
|---|---|
| Trial | TAISHAN‑302 – Phase III registrational study (interim analysis) |
| Investigational Drug | Tambotatug pelitecan (Tam‑Peli; YL201), a B7‑H3‑targeted ADC |
| Comparator | Topotecan (standard second‑line chemotherapy) |
| Population | Relapsed SCLC after prior platinum‑based chemotherapy ± PD‑L1 inhibitor |
| Primary Endpoint | Overall survival – met |
| Results Date | Announced 13 Sep 2026 |
| Next Steps | Not disclosed; registrational filing timing not specified |
Clinical Evidence – TAISHAN‑302 Interim Analysis
| Endpoint | Tambotatug Pelitecan | Topotecan | Relative Benefit |
|---|---|---|---|
| Median OS | 13.3 months | 9.4 months | +3.9 months |
| Risk of Death | – | – | 54 % reduction |
| Stratified Hazard Ratio | HR = 0.46 | – | – |
| Statistical Significance | p < 0.0001 | – | – |
The interim analysis shows Tam‑Peli nearly halving the risk of death versus topotecan – the chemotherapy standard that has anchored relapsed SCLC for decades. Secondary endpoints, safety profile details, and patient numbers were not disclosed in the announcement.
Drug Profile & Mechanism of Action
- Molecule: Tambotatug pelitecan (YL201), a B7‑H3‑targeting antibody‑drug conjugate (ADC).
- Platform: Built on MediLink’s proprietary Tumour Microenvironment‑Activatable Linker (TMALIN) platform, designed to activate payload release preferentially in the tumour microenvironment.
- Payload: A cleavable camptothecin‑based (topoisomerase I inhibitor) cytotoxic payload.
- Strategic Partnership: In January 2026, MediLink entered an exclusive licensing agreement with Roche, granting Roche exclusive global rights to develop, manufacture, and commercialize tambotatug pelitecan outside mainland China, Hong Kong SAR, and Macao SAR.
Market Impact & Outlook
- High Unmet Need: Relapsed SCLC carries a poor prognosis with limited options; topotecan’s modest survival benefit has left the second‑line setting ripe for disruption.
- Best‑in‑Class Signal: A 54 % reduction in the risk of death versus active chemotherapy is among the strongest phase III OS results reported in relapsed SCLC, positioning Tam‑Peli as a potential new standard of care.
- Global Commercial Path: The Roche partnership provides worldwide development and commercialization muscle outside Greater China, materially expanding the asset’s reach and market potential.
- Platform Validation: Positive registrational data validate the TMALIN ADC platform and strengthen MediLink’s pipeline credibility for future partnered programs.
- Filing Outlook: Regulatory submission plans and launch timing were not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical outcomes, regulatory timelines, and commercial expectations for tambotatug pelitecan (YL201). Interim results are subject to confirmation in final analyses. Actual results may differ due to risks including safety findings, regulatory review outcomes, market adoption, and competitive dynamics.-Fineline Info & Tech
